730 related articles for article (PubMed ID: 9669812)
1. Failure of fluconazole prophylaxis to reduce mortality or the requirement of systemic amphotericin B therapy during treatment for refractory acute myeloid leukemia: results of a prospective randomized phase III study. German AML Cooperative Group.
Kern W; Behre G; Rudolf T; Kerkhoff A; Grote-Metke A; Eimermacher H; Kubica U; Wörmann B; Büchner T; Hiddemann W
Cancer; 1998 Jul; 83(2):291-301. PubMed ID: 9669812
[TBL] [Abstract][Full Text] [Related]
2. Liposomal amphotericin B versus the combination of fluconazole and itraconazole as prophylaxis for invasive fungal infections during induction chemotherapy for patients with acute myelogenous leukemia and myelodysplastic syndrome.
Mattiuzzi GN; Estey E; Raad I; Giles F; Cortes J; Shen Y; Kontoyiannis D; Koller C; Munsell M; Beran M; Kantarjian H
Cancer; 2003 Jan; 97(2):450-6. PubMed ID: 12518369
[TBL] [Abstract][Full Text] [Related]
3. Randomized trial of fluconazole versus low-dose amphotericin B in prophylaxis against fungal infections in patients undergoing hematopoietic stem cell transplantation.
Koh LP; Kurup A; Goh YT; Fook-Chong SM; Tan PH
Am J Hematol; 2002 Dec; 71(4):260-7. PubMed ID: 12447954
[TBL] [Abstract][Full Text] [Related]
4. Efficiency and safety of inhaled amphotericin B lipid complex (Abelcet) in the prophylaxis of invasive fungal infections following lung transplantation.
Borro JM; Solé A; de la Torre M; Pastor A; Fernandez R; Saura A; Delgado M; Monte E; Gonzalez D
Transplant Proc; 2008 Nov; 40(9):3090-3. PubMed ID: 19010204
[TBL] [Abstract][Full Text] [Related]
5. Risk of reactivation of a recent invasive fungal infection in patients with hematological malignancies undergoing further intensive chemo-radiotherapy. A single-center experience and review of the literature.
Martino R; Lopez R; Sureda A; Brunet S; Domingo-Albós A
Haematologica; 1997; 82(3):297-304. PubMed ID: 9234575
[TBL] [Abstract][Full Text] [Related]
6. Empirical versus preemptive antifungal therapy for high-risk, febrile, neutropenic patients: a randomized, controlled trial.
Cordonnier C; Pautas C; Maury S; Vekhoff A; Farhat H; Suarez F; Dhédin N; Isnard F; Ades L; Kuhnowski F; Foulet F; Kuentz M; Maison P; Bretagne S; Schwarzinger M
Clin Infect Dis; 2009 Apr; 48(8):1042-51. PubMed ID: 19281327
[TBL] [Abstract][Full Text] [Related]
7. Randomized placebo-controlled trial of fluconazole prophylaxis for neutropenic cancer patients: benefit based on purpose and intensity of cytotoxic therapy. The Canadian Fluconazole Prophylaxis Study Group.
Rotstein C; Bow EJ; Laverdiere M; Ioannou S; Carr D; Moghaddam N
Clin Infect Dis; 1999 Feb; 28(2):331-40. PubMed ID: 10064252
[TBL] [Abstract][Full Text] [Related]
8. An open-label randomized trial comparing itraconazole oral solution with fluconazole oral solution for primary prophylaxis of fungal infections in patients with haematological malignancy and profound neutropenia.
Glasmacher A; Cornely O; Ullmann AJ; Wedding U; Bodenstein H; Wandt H; Boewer C; Pasold R; Wolf HH; Hänel M; Dölken G; Junghanss C; Andreesen R; Bertz H;
J Antimicrob Chemother; 2006 Feb; 57(2):317-25. PubMed ID: 16339606
[TBL] [Abstract][Full Text] [Related]
9. A prospective randomized trial of itraconazole vs fluconazole for the prevention of fungal infections in patients with acute leukemia and hematopoietic stem cell transplant recipients.
Oren I; Rowe JM; Sprecher H; Tamir A; Benyamini N; Akria L; Gorelik A; Dally N; Zuckerman T; Haddad N; Fineman R; Dann EJ
Bone Marrow Transplant; 2006 Jul; 38(2):127-34. PubMed ID: 16751782
[TBL] [Abstract][Full Text] [Related]
10. Invasive fungal infections in pediatric leukemia patients receiving fluconazole prophylaxis.
Kaya Z; Gursel T; Kocak U; Aral YZ; Kalkanci A; Albayrak M
Pediatr Blood Cancer; 2009 Apr; 52(4):470-5. PubMed ID: 19058205
[TBL] [Abstract][Full Text] [Related]
11. Prophylactic action of oral fluconazole against fungal infection in neutropenic patients. A meta-analysis of 16 randomized, controlled trials.
Kanda Y; Yamamoto R; Chizuka A; Hamaki T; Suguro M; Arai C; Matsuyama T; Takezako N; Miwa A; Kern W; Kami M; Akiyama H; Hirai H; Togawa A
Cancer; 2000 Oct; 89(7):1611-25. PubMed ID: 11013378
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of different prophylactic antifungal regimens in bone marrow transplantation.
Annaloro C; Oriana A; Tagliaferri E; Bertolli V; Della Volpe A; Soligo D; Ibatici A; Pozzoli E; Lambertenghi Deliliers GL
Haematologica; 1995; 80(6):512-7. PubMed ID: 8647515
[TBL] [Abstract][Full Text] [Related]
13. Fluconazole as prophylaxis against fungal infection in patients with advanced HIV infection.
Manfredi R; Mastroianni A; Coronado OV; Chiodo F
Arch Intern Med; 1997 Jan; 157(1):64-9. PubMed ID: 8996042
[TBL] [Abstract][Full Text] [Related]
14. Fluconazole versus amphotericin B for the prevention of fungal infection in neutropenic patients with hematologic malignancy.
Takatsuka H; Takemoto Y; Okamoto T; Fujimori Y; Tamura S; Wada H; Okada M; Kanamaru A; Kakishita E
Drugs Exp Clin Res; 1999; 25(4):193-200. PubMed ID: 10442277
[TBL] [Abstract][Full Text] [Related]
15. A randomized study of the use of fluconazole in continuous versus episodic therapy in patients with advanced HIV infection and a history of oropharyngeal candidiasis: AIDS Clinical Trials Group Study 323/Mycoses Study Group Study 40.
Goldman M; Cloud GA; Wade KD; Reboli AC; Fichtenbaum CJ; Hafner R; Sobel JD; Powderly WG; Patterson TF; Wheat LJ; Stein DK; Dismukes WE; Filler SG; ;
Clin Infect Dis; 2005 Nov; 41(10):1473-80. PubMed ID: 16231260
[TBL] [Abstract][Full Text] [Related]
16. [Comparison of oral fluconazole and amphotericin B prophylaxis against fungal infections in the neutropenic phase of patients treated with antileukemic agents].
Finke R
Mycoses; 1990; 33 Suppl 1():42-54. PubMed ID: 2101864
[TBL] [Abstract][Full Text] [Related]
17. Evidence-based review of antifungal prophylaxis in neutropenic patients with haematological malignancies.
Glasmacher A; Prentice AG
J Antimicrob Chemother; 2005 Sep; 56 Suppl 1():i23-i32. PubMed ID: 16120631
[TBL] [Abstract][Full Text] [Related]
18. Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses Study Group.
Walsh TJ; Finberg RW; Arndt C; Hiemenz J; Schwartz C; Bodensteiner D; Pappas P; Seibel N; Greenberg RN; Dummer S; Schuster M; Holcenberg JS
N Engl J Med; 1999 Mar; 340(10):764-71. PubMed ID: 10072411
[TBL] [Abstract][Full Text] [Related]
19. Galactomannan and computed tomography-based preemptive antifungal therapy in neutropenic patients at high risk for invasive fungal infection: a prospective feasibility study.
Maertens J; Theunissen K; Verhoef G; Verschakelen J; Lagrou K; Verbeken E; Wilmer A; Verhaegen J; Boogaerts M; Van Eldere J
Clin Infect Dis; 2005 Nov; 41(9):1242-50. PubMed ID: 16206097
[TBL] [Abstract][Full Text] [Related]
20. Risks and outcome of fungal infection in neutropenic children with hematologic diseases.
Aytaç S; Yildirim I; Ceyhan M; Cetin M; Tuncer M; Kara A; Cengiz AB; Seçmeer G; Yetgin S
Turk J Pediatr; 2010; 52(2):121-5. PubMed ID: 20560245
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]